Envista Holdings Corporation (NVST) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, NVST carries an RQD score of 49, a letter grade of D, and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are scored as follows:

• Fundamental Cash Engine: 7 / 20. Per the RQD rating, this pillar reflects ROIC of 5.1% and an FCF yield of 5.83%. For an investor, returns on invested capital in the low single digits signal that the company is generating limited value relative to the capital deployed, and the FCF yield indicates the cash-generation case is modest at the current price.
• Whale / 13F Flow: 11 / 20. Per the RQD rating, this pillar covers institutional accumulation and options positioning. The underlying holder data is not provided in this source set, so the score cannot be traced to specific institutional activity here.
• Insider Conviction: 11 / 20. Per the RQD rating, this pillar covers SEC Form 4 and Congressional PTR cluster flow. The underlying trade-level data is not provided in this source set.
• Macro Regime Fit: 8 / 20. Per the RQD rating, beta is 0.93 with sector sensitivity considered. A beta below 1 suggests the stock has historically moved less than the broad market, but the low pillar score indicates the regime-fit case is weak.
• Forensic Balance Sheet: 12 / 20. Per the RQD rating, this pillar reflects an Altman Z of 1.61, a Piotroski F of 9/9, and a Debt/Equity of 0.47. The Piotroski reading is strong, while the Altman Z sits in a range that is conventionally treated as a distress-adjacent zone, creating a mixed forensic picture.

Taken together, the score says the stock screens weakly on cash returns and regime fit, with a relatively stronger balance-sheet quality reading. The valuation tradeoff is significant: per the market data, the P/E (TTM) is 84.1 against EPS (TTM) of 0.29, so the price embeds expectations far above current trailing earnings. The upside case depends on earnings expansion that the trailing figures do not yet show, and the rating's distribution warning reflects that the current data does not confirm it.

Envista Holdings Corporation is a NYSE-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry. Per the profile, the company's market capitalization is $4.0B. Per the market data, its gross margin is 54.7%, indicating a high-margin product mix. Details of specific products, customers, and revenue streams are not available in source data.

Per the SEC financials, FY 2025 shows a return to positive operating and net income after a large loss in FY 2024. Per the market data, the operating margin is 7.9% and the net margin is 1.7%, while ROIC is 5.1%. Per the RQD rating, the Altman Z is 1.61 and the Piotroski F is 9/9. Debt rose from $720.7M in FY 2023 to $1448.3M in FY 2025, while reported cash was $1211.7M in FY 2025.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Sector: Health Care; industry: Medical/Dental Instruments. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are not available in source data.

• What drove the FY 2024 operating loss of $-1038.2M, and was it non-recurring?
• What is the reported EPS for any period, given that EPS is N/A across all three filings?
• Which products and end markets generate the revenue, and how is it split geographically?
• How much of the debt increase from FY 2023 to FY 2025 relates to specific financing or acquisition activity?
• Who are the institutional and insider holders, and what is their recent activity?